Ginkgo Bioworks Holdings, Inc. (DNA): Total Liabilities
$611.11M
As of 2025-12-31
$569.76M
As of 2026-06-30
-8.7%
3-year compound annual growth
+24.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $611.11M | -7.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $661.39M | +16.4% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $568.19M | -29.2% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $803.04M | +59.5% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $503.61M | +145.5% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $205.10M | n/a | 2022-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $611.11M | -7.6% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $350.30M | +69.8% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $234.11M | -3.7% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $242.82M | -34.4% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $214.59M | +7.3% |
Compare DNA, RGNX, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗